Możliwy korzystny efekt blokerów układu RAAS u pacjentów z COVID-19

Brojakowska A i wsp. Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System.  J Am Coll Cardiol. 2020 online (dostępny pełen tekst)

Thus, in patients with cardiovascular disease and SARS-CoV2, the use of ACE inhibitors, ARBs, or MRAs may be favorable as a method to endogenously upregulate ACE2 as a compensatory mechanism that provides anti-inflammatory, anti-fibrotic and anti-thrombotic support as well as reduction in progression of vascular/cardiac remodeling and heart failure …

Journal of American College of Cardiology,  16 marca 2020

Dodaj komentarz